18F-Fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response

International Journal of Clinical Oncology

Volumn 17, Issue 3, 2012, Pages 276-282

  Ueda, Shigeto ^a,b   Saeki, Toshiaki ^b   Shigekawa, Takashi ^b   Omata, Jiro ^c   Moriya, Tomoyuki ^c   Yamamoto, Junji ^c   Osaki, Akihiko ^d   Fujiuchi, Nobuko ^b   Misumi, Misono ^b   Takeuchi, Hideki ^b   Sakurai, Takaki ^b   Tsuda, Hitoshi ^e   Tamura, Katsumi ^f   Ishida, Jiro ^f   Abe, Yoshiyuki ^f   Imabayashi, Etsuko ^b   Kuji, Ichiei ^b   Matsuda, Hiroshi ^b  

^a Medical Service School   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL   (Japan)

^f Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

Author keywords

Anthracycline; pCR; SUV; Taxane

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; PACLITAXEL; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TAXANE; TAXOID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; ADJUVANT THERAPY; BREAST TUMOR; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROSPECTIVE STUDY; SCINTISCANNING;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TAXOIDS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84862886064     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0287-2     Document Type: Article

References (29)

1. De Laurentiis M, Cancello G, Zinno L et al (2005) Targeting HER2 as a therapeutic strategy for breast cancer: a paradigmatic shift of drug development in oncology. Ann Oncol 16(Suppl 4):iv7-iv13
2. Ferguson T, Wilcken N, Vagg R et al (2007) Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007(4):CD004421
3. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21(6):976-983
4. Mamounas EP, Bryant J, Lembersky B et al (2005) Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 23(16):3686-3696
5. Sachelarie I, Grossbard ML, Chadha M et al (2006) Primary systemic therapy of breast cancer. Oncol 11(6):574-589
6. Kaufmann M, von Minckwitz G, Bear HD et al (2007) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 18(12):1927-1934
7. Caudle AS, Gonzalez-Angulo AM, Hunt KK et al (2010) Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. J Clin Oncol 28(11):1821-1828
8. van de Vijver MJ, He YD, van't Veer LJ et al (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347(25):1999-2009
9. Juweid ME, Cheson BD (2006) Positron-emission tomography and assessment of cancer therapy. N Engl J Med 354(5):496-507
10. Young H, Baum R, Cremerius U et al (1999) Measurement of clinical and subclinical tumour response using [18F]-fluorode-oxyglucose and positron emission tomography: review and 1999. EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 35(13):1773-1782
11. Shankar LK, Hoffman JM, Bacharach S et al (2006) Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials. J Nucl Med 47(6):1059-1066
12. Avril N, Rose CA, Schelling M et al (2000) Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglu-cose: use and limitations. J Clin Oncol 18(20):3495-3502
13. Schelling M, Avril N, Nahrig J et al (2000) Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 18(8): 1689-1695
14. Rousseau C, Devillers A, Sagan C et al (2006) Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography. J Clin Oncol 24(34):5366-5372
15. Smith IC, Welch AE, Hutcheon AW et al (2000) Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 18(8):1676-1688
16. Schwarz-Dose J, Untch M, Tiling R et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol 27(4):535-541
17. Beresford MJ, Wilson GD, Makris A (2006) Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 8(6):216
18. Podoloff DA, Ball DW, Ben-Josef E et al (2009) NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw 7(Suppl 2):1-26
19. Ueda S, Tsuda H, Asakawa H et al (2008) Clinicopathological and prognostic relevance of uptake level using 18F-fluorode-oxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol 38(4):250-258
20. Ueda S, Kondoh N, Tsuda H et al (2008) Expression of centromere protein F (CENP-F) associated with higher FDG uptake on PET/CT, detected by cDNA microarray, predicts high-risk patients with primary breast cancer. BMC Cancer 8:384
21. Ueda S, Tsuda H, Saeki T et al (2010) Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Breast Cancer. doi:10.1007/s12282-010-0212-y
22. Ito K, Kubota K, Morooka M et al (2009) Diagnostic usefulness of 18F-FDG PET/CT in the differentiation of pulmonary artery sarcoma and pulmonary embolism. Ann Nucl Med 23(7): 671-676
23. Kurosumi M, Akashi-Tanaka S, Akiyama F et al (2008) Histo-pathological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer (Tokyo, Japan) 15(1):5-7
24. Hayes DF, Thor AD, Dressler LG et al (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357(15):1496-1506
25. Bedard PL, Di Leo A, Piccart-Gebhart MJ (2010) Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev 7(1):22-36
26. Buzdar AU, Ibrahim NK, Francis D et al (2005) Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23(16):3676-3685
27. Buzdar AU, Valero V, Ibrahim NK et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trast-uzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-233
28. Straver ME, Aukema TS, Olmos RA et al (2010) Feasibility of FDG PET/CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients. Eur J Nucl Med Mol Imag 37(6):1069-1076
29. Ueda S, Tsuda H, Asakawa H et al (2008) Utility of 18F-fluoro- deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultra-sonography for axillary staging in primary breast cancer. BMC Cancer 8:165